The Value of Blood Tumor Markers in the Prognosis of Patients with Unresectable Locally Advanced or Metastatic Gastric Cancer before First-line Chemotherapy
SUN Zhi-wei
JIA Jun
DU Feng
LIU Chuan-ling
YU Jing
YANG Ying
XIAO Yan-jie
ZHANG Xiao-dong
1.Vip-Ⅱ Ward, Oncology Department, Peking University Cancer Hospital and Beijing Institute of Cancer Prevention and Control, Key Laboratory of Cancer Pathogenesis and Transformation Research, Ministry of Education,Beijing 100142, China2.Vip-Ⅱ Ward, Oncology Department, Peking University Cancer Hospital and Beijing Institute of Cancer Prevention and Control, Key Laboratory of Cancer Pathogenesis and Transformation Research, Ministry of Education,Beijing 100142, China3.Vip-Ⅱ Ward, Oncology Department, Peking University Cancer Hospital and Beijing Institute of Cancer Prevention and Control, Key Laboratory of Cancer Pathogenesis and Transformation Research, Ministry of Education,Beijing 100142, China4.Vip-Ⅱ Ward, Oncology Department, Peking University Cancer Hospital and Beijing Institute of Cancer Prevention and Control, Key Laboratory of Cancer Pathogenesis and Transformation Research, Ministry of Education,Beijing 100142, China5.Vip-Ⅱ Ward, Oncology Department, Peking University Cancer Hospital and Beijing Institute of Cancer Prevention and Control, Key Laboratory of Cancer Pathogenesis and Transformation Research, Ministry of Education,Beijing 100142, China6.Vip-Ⅱ Ward, Oncology Department, Peking University Cancer Hospital and Beijing Institute of Cancer Prevention and Control, Key Laboratory of Cancer Pathogenesis and Transformation Research, Ministry of Education,Beijing 100142, China7.Vip-Ⅱ Ward, Oncology Department, Peking University Cancer Hospital and Beijing Institute of Cancer Prevention and Control, Key Laboratory of Cancer Pathogenesis and Transformation Research, Ministry of Education,Beijing 100142, China8.Vip-Ⅱ Ward, Oncology Department, Peking University Cancer Hospital and Beijing Institute of Cancer Prevention and Control, Key Laboratory of Cancer Pathogenesis and Transformation Research, Ministry of Education,Beijing 100142, China
摘要：Objective:To study the significance of CEA,CA199,CA72.4 and CA125 in the peripheral blood of patients with advanced or metastatic gastric cancer.Methods:The clinical data of 109 patients with non-operative local advanced or metastatic gastric cancer who received first-line chemotherapy in our center from July 2013 to May 2015,and the detection results of CEA,CA199,CA72.4 and CA125 tumor markers before chemotherapy were retrospectively collected,and their correlation with the clinicopathological characteristics and prognosis of the patients were analyzed.Results:The positive rates of CEA,CA199,CA72.4 and CA125 were 46.8％,40.2％,53.5％ and 35.0％ respectively in 109 cases of gastric cancer,and the positive rates of combined detection of four markers were 87.2％.CEA positive was significantly correlated with liver metastasis (P=0.014),CA125 positive with peritoneal metastasis (P=0.005).In univariate analysis,median PFS (6.3 months vs 11.1 months,P=0.020) and median OS (9.9 months vs 16.9 months,P=0.007) of CA72.4 positive subjects were significantly shorter than those of negative subjects,and median PFS (6.2 months vs 7.8 months,P=0.002) and median OS (9.8 months vs 15.6 months,P=0.009) of CA125 positive subjects were significantly shorter than those of negative subjects.95％ CI 1.016-29.601).Of 109 patients,49 (45.0％) were low-risk group (0 or 1 risk factor),60 (55.0％) were high-risk group (2 to 4 risk factors).The median survival time of low-risk and high-risk groups was 18.5 months and 9.9 months,respectively (P=0.001).Conclusion:CA72.4 and CA125 are related to the prognosis of patients with local advanced or metastatic gastric cancer,and the prognosis model is helpful to stratify the risk of patients and provide the best treatment plan for each patient.
机标关键词：
分类号：R735.2(消化系肿瘤)
论文发表日期：2019-03-30
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：12( 1-12 )
英文信息